Not Signed In -
Penciclovir Cream |
Denavir |
Clinical Trial: A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
This study is no longer recruiting patients.
|
Purpose
To assess whether BCC lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will have an improved cure rate over the ED/C historical norm of approximately 70% at 1-year posttreatment follow up. A secondary objective is to assess cosmetic outcome.
| Condition | Intervention | Phase |
|---|---|---|
| Basal Cell Carcinoma | Drug: Imiquimod 5% cream | Phase III |
MedlinePlus related topics: Skin Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title: Open-Label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage
Further Study Details:
Primary Outcomes: Efficacy
Secondary Outcomes: cosmetic outcome
Expected Total Enrollment: 66
Secondary Outcomes: cosmetic outcome
Expected Total Enrollment: 66
Study start: January 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Location Information
California
Grass Valley, California, 95945, United States
Loma Linda, California, 92354, United States
New York
New York, New York, 10016, United States
More Information
Study ID Numbers: 1491-IMIQ
Last Updated: August 11, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00129519
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 11, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00129519
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Denavir (Drug Digest)
- Penciclovir Cream (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
